A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2027-10-30
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the safety, tolerability, pharmacokinetic profile, and
antitumor efficacy of DZD8586 in participants with relapsed or refractory B-NHL.